BCAX
Bicara Therapeutics Inc.
28.91
2 x 21.16
2 x 36.97
bid
ask
-
0.78
2.63%
2 @ 04:00 PM
29.25 +0.34 (1.18%)
| Ytd | 71.78% | |
| 1y | 205.60% |
28.78
day range
29.90
8.74
52 week range
29.90
| Open | 29.36 | Prev Close | 29.69 | Low | 28.78 | High | 29.90 | Mkt Cap | 1.90B |
| Vol | 834.56K | Avg Vol | 663.35K | EPS | -2.77 | P/E | N/A | Forward P/E | -7.96 |
| Beta | N/A | Short Ratio | 20.56 | Inst. Own | 104.35% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 22.47 | 200-d Avg | 18.48 | 1yr Est | 31.46 |
| Income Statement | |||
| Operating Expenses | 60.24M | ||
| Research and Development Expense | 47.50M | ||
| Selling, General and Administrative Expense | 12.74M | ||
| Operating Income | -60.24M | ||
| Income Tax Expense | 52.00K | ||
| Net Income | -56.21M | ||
| Net Income Common Stock | -56.21M | ||
| Net Income Common Stock (USD) | -56.21M | ||
| Consolidated Income | -56.21M | ||
| Earnings per Basic Share | -0.93 | ||
| Earnings per Basic Share (USD) | -0.93 | ||
| Earnings per Diluted Share | -0.93 | ||
| Earning Before Interest & Taxes (EBIT) | -56.16M | ||
| Earning Before Interest & Taxes (USD) | -56.16M | ||
| Weighted Average Shares | 60.72M | ||
| Weighted Average Shares Diluted | 60.72M | ||
| Balance Sheet | |||
| Cash and Equivalents | 323.46M | ||
| Cash and Equivalents (USD) | 323.46M | ||
| Investments | 216.29M | ||
| Investments Current | 216.29M | ||
| Current Assets | 544.92M | ||
| Property, Plant & Equipment Net | 1.77M | ||
| Total Assets | 553.60M | ||
| Debt Current | 1.14M | ||
| Total Debt | 1.44M | ||
| Current Liabilities | 39.34M | ||
| Debt Non-Current | 301.00K | ||
| Total Liabilities | 39.64M | ||
| Accumulated Retained Earnings (Deficit) | -415.18M | ||
| Accumulated Other Comprehensive Income | -243.00K | ||
| Shareholders Equity | 513.96M | ||
| Shareholders Equity (USD) | 513.96M | ||
| Assets Non-Current | 8.68M | ||
| Total Debt (USD) | 1.44M | ||
| Liabilities Non-Current | 301.00K | ||
| Trade and Non-Trade Payables | 7.44M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 317.00K | ||
| Net Cash Flow from Financing | 163.35M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 226.78M | ||
| Capital Expenditure | -60.00K | ||
| Issuance (Purchase) of Equity Shares | 163.35M | ||
| Net Cash Flow from Investing | 100.94M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 101.00M | ||
| Net Cash Flow from Operations | -37.51M | ||
| Share Based Compensation | 5.86M | ||